effimune
Effimune is developping new immunomodulators in autoimmunity and transplantation to restore the immune system and to reduce side effects.
- Stage Product In Development
- Industry Biotechnology
- Location Nantes, Pays de la Loire, France
- Currency EUR
- Founded February 2007
- Employees 8
- Website effimune.com
Company Summary
Effimune is developing 3 monoclonal antibodies : FR104, EFfi7-h and MP196 which are selectively blocking effector T cells while enhancing regulatory T cells responses. The FR104, first in class has the potential to restore the immune tolerance which is deficient in patients suffering from some autoimmune diseases or after organ or cells transplantation.
Team
-
Maryvonne HianceChairman
-
Bernard VanhoveR&D Director
-
Jean Paul SoulillouSAB Chairman
-
Didier CoquozDevelopment & regulatory Affairs
Advisors
-
HBC/ Cornet Vincent SégurelLawyerUnconfirmedIn Extenso Ouest AtlantiqueAccountantUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.